Characterization of oral immune cells in birch pollen-allergic patients: Impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen-presenting cells

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 4, 2015, Pages 408-419

  Mascarell, L ^a   Rak, S ^b   Worm, M ^c   Melac, M ^a   Soulie, S ^a   Lescaille, G ^d,e,f   Lemoine, F ^f   Jospin, F ^g   Paul, S ^g   Caplier, L ^h   Hasseus B ^b   Bjorhn C ⁱ   Zeldin, R K ^a   Baron Bodo, V ^a   Moingeon, P ^a  

^a Research and Development   (France)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Assistance publique Hôpitaux de Paris   (France)

^g INSERM   (France)

^h BiodOxis   (France)

ⁱ Västerås Hospital   (Sweden)

Author keywords

birch allergy; IgE; macrophages; mucosal immunity; sublingual allergen immunotherapy

Indexed keywords

CD68 ANTIGEN; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN E; LANGERIN; STEM CELL FACTOR RECEPTOR; ALLERGEN; BIOLOGICAL MARKER; MEMBRANE ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; BIRCH POLLEN ALLERGY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOLOGY; LAMINA PROPRIA; LANGERHANS CELL; MACROPHAGE; MAST CELL; MYELOID DENDRITIC CELL; ORAL ALLERGY SYNDROME; PHASE 3 CLINICAL TRIAL; POLLEN ALLERGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL ALLERGEN IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE; TREATMENT DURATION; BIOPSY; BIRCH; CASE CONTROL STUDY; FEMALE; GENE EXPRESSION; GENETICS; GINGIVA; HYPERSENSITIVITY; IMMUNOLOGY; IMMUNOPHENOTYPING; MALE; METABOLISM; PATHOLOGY; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SYNDROME; T LYMPHOCYTE SUBPOPULATION;

ALLERGENS; ANTIGEN-PRESENTING CELLS; ANTIGENS, SURFACE; BETULA; BIOMARKERS; BIOPSY; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; GINGIVA; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOPHENOTYPING; MACROPHAGES; MALE; MAST CELLS; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SUBLINGUAL IMMUNOTHERAPY; SYNDROME; T-LYMPHOCYTE SUBSETS;

EID: 84925588626     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12576     Document Type: Article

References (31)

1. Wilson DR, Lima MT, Durham SR,. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60: 4-12.
2. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118: 434-440.
3. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120: 1338-1345.
4. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123: 160-166.
5. Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Devillier P, Montagut A, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009; 124: 471-477.
6. Canonica G, Bousquet J, Casale T, Lockey R, Baena-Cagnani C, Pawankar R, et al. Sub-lingual Immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009; 64: 1-59.
7. Compalati E, Passalacqua G, Bonini M, Canonica GW,. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009; 64: 1570-1579.
8. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125: 131-138.
9. Moingeon P,. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract 2013; 1: 228-241.
10. Akdis M, Akdis CA,. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 2014; 133: 621-631.
11. + T cells. J Allergy Clin Immunol 2008; 122: 603-609.
12. Mascarell L, Saint-Lu N, Moussu H, Zimmer A, Louise A, Lone Y, et al. Oral macrophage-like cells play a key role in tolerance induction following sublingual immunotherapy of asthmatic mice. Mucosal Immunol 2011; 4: 638-647.
13. Allam JP, Novak N, Fuchs C, Asen S, Berge S, Appel T, et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 2003; 112: 141-148.
14. Allam JP, Bieber T, Novak N,. Dendritic cells as potential targets for mucosal immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9: 554-557.
15. Allam JP, Novak N,. Local immunological mechanisms of sublingual immunotherapy. Curr Opin Allergy Clin Immunol 2011; 11: 571-578.
16. Bohle B,. The impact of pollen-related food allergens on pollen allergy. Allergy 2007; 62: 3-10.
17. Worm M, Rak S, de Blay F, Malling HJ, Melac M, Cadic V, et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. Clin Transl Allergy 2014; 4: 7.
18. + T cells. Clin Exp Allergy 2009; 39: 1910-1919.
19. Marcucci F, Sensi L, Incorvaia C, Di Cara G, Moingeon P, Frati F,. Oral reactions to sublingual immunotherapy: a bioptic study. Allergy 2007; 62: 1475-1477.
20. Allam JP, Stojanovski G, Friedrichs N, Peng W, Bieber T, Wenzel J, et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 2008; 63: 720-727.
21. Allam JP, Duan Y, Winter J, Stojanovski G, Fronhoffs F, Wenghoefer M, et al. Tolerogenic T cells, Th1/Th17 cytokines and TLR2/TLR4 expressing dendritic cells predominate the microenvironment within distinct oral mucosal sites. Allergy 2011; 66: 532-539.
22. Palomares O, Ruckert B, Jartti T, Kucuksezer UC, Puhakka T, Gomez E, et al. Induction and maintenance of allergen-specific FOXP3 + Treg cells in human tonsils as potential first-line organs of oral tolerance. J Allergy Clin Immunol 2012; 129: 510-520.
23. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13: 145-149.
24. Van Overtvelt L, Wambre E, Maillere B, von Hofe E, Louise A, Balazuc AM, et al. Assessment of Bet v 1-specific CD4 + T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. J Immunol 2008; 180: 4514-4522.
25. Geroldinger-Simic M, Zelniker T, Aberer W, Ebner C, Egger C, Greiderer A, et al. Birch pollen-related food allergy: clinical aspects and the role of allergen-specific IgE and IgG4 antibodies. J Allergy Clin Immunol 2011; 127: 616-622.
26. Allam JP, Wurtzen PA, Reinartz M, Winter J, Vrtala S, Chen KW, et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol 2010; 126: 638-645.
27. Lima MT, Wilson D, Pitkin L, Roberts A, Nouri-Aria K, Jacobson M, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32: 507-514.
28. Scadding GW, Shamji MH, Jacobson MR, Lee DI, Wilson D, Lima MT, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40: 598-606.
29. Calderõn MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P,. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012; 67: 302-311.
30. Razafindratsita A, Saint-Lu N, Mascarell L, Berjont N, Bardon T, Betbeder D, et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007; 120: 278-285.
31. Moingeon P,. Sublingual immunotherapy: from biological extracts to recombinant allergens. Allergy 2006; 61: 15-19.